CellRapeutics™ In Vivo Peripheral Blood Mononuclear Cell (PBMC) Engineering Service

Background of Our Technology

Peripheral blood mononuclear cells (PBMCs) are critical components of the human immune system, comprising T cells, B cells, NK cells, and monocytes. They serve as a powerful foundation for cellular immunotherapies. Our platform leverages an innovative modified T central memory (mTCM) engineering approach to reprogram PBMCs into potent anti-tumor immune responders. By delivering tumor-associated antigens (TAAs) or synthetic peptide epitopes into PBMCs, and promoting their differentiation via cytokine cocktails, we generate dendritic cells (DCs) capable of cross-presenting multi-targeted antigens. These DCs induce the formation of tumor-targeting TCM cells with superior persistence, self-renewal capacity, and broad tumor recognition, setting a new paradigm for in vivo immunomodulation.

Fig.1 Separation process of PBMC.¹

Our In Vivo Peripheral Blood Mononuclear Cell Engineering Services

At Creative Biolabs, our in vivo PBMC engineering service encompasses:

• Antigen Design & Vector Engineering: Customization of tumor-associated epitope peptides or genetic constructs for TAA delivery.
• PBMC Isolation and Infection: Isolation of high-purity PBMCs followed by infection using viral or non-viral systems to express TAAs in monocytes and DC precursors.
• Cytokine-Induced Differentiation: Application of IL-4, GM-CSF, TNF-α, and other cytokines to drive dendritic cell differentiation and functional maturation.
• mTCM Generation: Activation of T cells by antigen-loaded DCs to enrich central memory phenotypes (CD62L⁺CCR7⁺) with polyfunctional properties.
• In Vivo Assessment: Preclinical testing of mTCM cells in murine tumor models for anti-tumor efficacy, persistence, and multi-target cytotoxicity.

We provide both standalone and integrated services, from construct design to in vivo evaluation, tailored to translational immunotherapy research.

Why Choose Us

• Multi-Antigen Targeting

Unlike traditional single-target approaches, our mTCM platform introduces multiple tumor-specific and pan-cancer epitopes into DCs, enabling a broader and more adaptive immune attack.

• Enhanced Memory and Durability

The engineered TCM population exhibits long-term persistence, maintaining surveillance and anti-tumor functions even post-treatment, reducing relapse risks.

• Streamlined Workflow

From PBMC isolation to final in vivo validation, we offer a one-stop platform with expert guidance and quality assurance at each stage.

• Cryogen-Free Flexibility

Our system minimizes reliance on cell freezing and recovery, allowing rapid turnaround for time-sensitive studies.

• Safety and Non-Pathogenic Design

Our antigen delivery vectors are optimized to be non-integrative and non-replicative, ensuring biosafety for in vivo use.

Step-by-Step Service Workflow

To streamline your research process, we've designed a transparent and customizable workflow:

Published Data

Our mTCM-based PBMC engineering approach has been referenced in multiple peer-reviewed studies and conference abstracts. Recent preclinical publications have demonstrated:

• Prolonged T cell memory in mouse xenograft models of solid tumors.
• Effective elimination of tumor cells expressing immune suppressive markers.
• Reduction of metastatic potential by targeting MMP-secreting cancer cells.

Frequently Asked Questions

Q1: What types of tumors can mTCM technology target?

A1: Our system is adaptable to both hematologic malignancies and solid tumors by customizing the antigen cargo.

Q2: Are patient-derived PBMCs required?

A2: We support both autologous and allogeneic PBMC sources, depending on your study design and ethical approvals.

Q3: Can this service be integrated into CAR-T or TCR-T workflows?

A3: Yes. Our mTCM induction step can serve as a priming platform for downstream genetic modifications like CAR insertion.

Contact Us

At Creative Biolabs, we're committed to advancing in vivo immune modulation through innovation and partnership. Whether you are exploring preclinical efficacy, developing a novel T cell therapy, or seeking multi-target immunoengineering solutions, we are here to accelerate your success.

Reference

1. Patrone, Deanira et al. "Optimization of Peripheral Blood Mononuclear Cell Extraction from Small Volume of Blood Samples: Potential Implications for Children-Related Diseases." Methods and protocols vol. 5,2 20. 24 Feb. Distributed under Open Access License CC BY 4.0, without modification.